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Abstract of thesis 
 
（Purpose） 
Mitochondrial dysfunction has been identified as one of the primary factors contributing to 
liver diseases. The author, Mr. Rashad Mogalli, took note of mitochondrial biogenesis pathways 
and its potential therapeutic target molecules for the amelioration of hepatocyte dysfunction 
and liver disease. Research on natural pharmacological agents that ameliorate liver diseases 
has intensified over the last two decades. Cyanidin-3-glucoside (Cy3g), a dietary flavonoid 
compound extracted from a wide variety of fruits and vegetables, reportedly has several 
beneficial health effects. In this study, he used an adult human hepatoma cell line (HuH7) 
to investigate the effects of the Cy3g polyphenolic compound on mitochondrial function and 
biogenesis in vitro. 
 
（Materials and Methods） 
Cy3g (98% HPLC Purity) was purchased from Tokiwa Phytochemical Co., Ltd. Japan. The well-
differentiated human hepatocellular carcinoma HuH7 cell line was purchased from the National 
Institutes of Biomedical Innovation Health and Nutrition JCRB Bank (JCRB No. JCRB0403, Tokyo, 
Japan). Using the agent and cell line, the author performed MTT assay and Guava Count assay 
 to assess viable and apoptotic cells. To evaluate the mitochondrial function, ATP assay and 
mitochondrial membrane potential assay were performed. Furthermore, mRNA expression levels 
of mitochondrial function-related genes were measured by RT-PCR; peroxisome proliferator-
activated receptor -1 alpha (PGC-1α), sirtuin 1 (SIRT1), mitochondrial transcription factor 
A (TFAM), nuclear respiratory factor-1 (NRF1), carnitine palmitoyltransferase 1 beta (CPT-
1β), and phosphofructokinase 1 (PFK-1) were evaluated. 
 
（Results） 
The author found an increase in intracellular mitochondrial reductase levels after treatment 
with Cy3g, but not cytotoxic activity. In addition, mitochondrial membrane potential and ATP 
production were increased following Cy3g treatment. The author further revealed that Cy3g 
treatment also resulted in a dose- and time-dependent upregulation of the gene expression of 
PGC-1α, a transcription factor considered a master regulator of mitochondrial biogenesis and 
metabolism. Additionally, the expression of SIRT1, which plays a key role in deacetylating 
PGC-1α, was increased in a dose- and time-dependent manner. Next, the author studied the 
downstream gene expression of PGC-1α after Cy3g treatment, and confirmed NRF1 and TFAM were 
up-regulated. He found that this pathway contributed to amelioration of mitochondrial 
dysfunction of hepatocyte in Cy3g treatment.  
 
（Discussion） 
The author first mentions about Cy3g used in his study in the discussion section. Several 
studies have reported the beneficial effects of a variety of natural compounds, such as 
resveratrol, quercetin and catechin on health, and among anthocyanin compounds, Cy3g, a phenol 
pigment that belongs to the flavonoid family, has been shown to have beneficial effects in 
several in vitro and in clinical trials. Cy3g enhances skeletal muscle mitochondrial 
biogenesis by upregulating PGC-1α levels. PGC-1α is reportedly an essential factor for 
upregulating hepatic metabolism and is key for overall liver metabolism. These pre-existing 
reports seem to be a reason why the author used this compound, Cy3g, in his experiments, and 
it is considered feasible. His study examined the ability of Cy3g to increase mitochondrial 
function and biogenesis in HuH7 and elucidated the underlying mechanism.  
The author found that Cy3g induced PGC-1α. The induction of PGC-1α gene expression 
was associated with an increased SIRT1 gene expression. Increased expression of PGC-1α-
coactivated downstream genes, such as NRF1, which encodes respiratory chain subunits and 
other proteins necessary for mitochondrial function, was observed. Moreover, Cy3g increased 
the gene expression of TFAM, a nuclear-encoded transcription factor that plays a key role in 
mitochondrial DNA replication and transcription and is regulated by NRF1. Cy3g also increased 
CPT-1β gene expression, which is located within the mitochondrial outer membrane and is 
considered the rate-limiting enzyme of mitochondrial β-oxidation as CPT-1β controls the 
mitochondrial uptake of long chain acyl-CoA fatty acids. Cy3g also increased PFK-gene 
expression, an important regulator of glycolysis.  
The author here speculates a potential protective effect of Cy3g for hepatocyte from 
metabolic stress, and discusses with the reported literatures as follows. Currently, lifestyle 
modification and caloric restriction are the only treatments for nonalcoholic fatty liver 
diseases. Some polyphenol compounds, such as resveratrol, have shown calorie restriction-
mimicking effects in mammalian diseases and can ameliorate liver fat accumulation in high-
fat diet mouse models, mostly due to the activation of metabolism-sensing signaling systems. 
 While several pathways control mitochondrial function, biogenesis and free fatty acid 
oxidation, a recently identified member of peroxisome proliferator-activated receptor gamma 
coactivator family, PGC-1α, serves as a major regulator of the nuclear receptors that control 
metabolic pathways and is expressed in tissues with high oxidative capacity. Hepatocytes 
extracted from PGC-1α-deficient mice exhibit reduced mitochondrial respiration rates, 
indicating a reduced hepatic fatty acid oxidation capacity. SIRT1 coexists with the 
transcription factor PGC-1α  and plays an important role in PGC-1α activation via 
deacetylation. SIRT1 and PGC-1α signaling is important in the protection of in vitro 
hepatocyte models against mitochondrial oxidative stress. Furthermore, pharmacological 
activation of SIRT1 by polyphenol in HepG2 cells protected against FAS induction and lipid 
accumulation. Several studies have revealed the crucial role of sirtuins generally and SIRT1 
specifically in liver diseases. SIRT1, an NAD+ dependent protein deacetylase, is an important 
regulator of energy homeostasis, enhanced mitochondrial metabolism, antioxidative protection, 
lipid catabolism and glucose homeostasis. Both in vitro and in vivo models of SIRT1 deficiency 
have shown a tendency for increased lipid accumulation in the liver and downregulation of de 
novo hepatic lipid synthesis transcription factors, such as sterol regulatory element binding 
protein-1c and carbohydrate response element binding protein. 
Finally, the author discusses therapeutic potential of Cy3g, and of targeted-molecules 
on its signal transduction pathway. Pathways that control mitochondrial biogenesis have been 
studied extensively to identify future therapeutic approaches to treat the mitochondrial 
dysfunction that leads to various liver and metabolic diseases. His experiments showed that 
in a human-derived hepatocyte HuH7, Cy3g is a potent activator of the SIRT1 and PGC-1α 
signaling pathways, inducing mitochondrial biogenesis and function and triggering an increase 
in PGC-1α downstream genes, and these effects are dose- and time-dependent. Therefore, he 
concluded that this compound should be considered a therapeutic or preventive approach for 
diseases caused by hepatic cell mitochondrial dysfunction. 
 
 
Abstract of assessment result 
 
（General Comments） 
In this paper, the author evaluated the effects of Cy3g on human liver mitochondrial function 
and biogenesis, using a human-derived hepatocyte HuH7. Cy3g is a dietary flavonoid compound 
extracted from a wide variety of fruits and vegetables. It is easily available in daily life. 
He studied the effects with a variety of methods, and suggested that Cy3g enhanced 
mitochondrial function and biogenesis, and had potential as a hepatoprotective therapeutic 
agent. Furthermore, he examined the intracellular signal pathway on which Cy3g worked, and 
confirmed the contribution of SIRT1 and PGC-1α signaling. PGC-1α has been reported as an 
inhibitor of mitochondrial oxidative stress and modulator of fatty acids. These findings are 
considered to be important for the future clinical development of therapeutics in patients 
who have hepatic dysfunction due to fatty liver. 
 
（Assessment） 
The final examination committee conducted a meeting as a final examination on December 26, 
2018. The applicant provided an overview of dissertation, addressed questions and comments 
 raised during Q&A session. All of the committee members reached a final decision that the 
applicant has passed the final examination. 
 
（Conclusion） 
The final examination committee approved that the applicant is qualified to be awarded Doctor 
of Philosophy in Medical Sciences. 
 
